Castle Biosciences Test Predicts JAK Inhibitor Response in Atopic Dermatitis
Castle Biosciences' AdvanceAD-Tx test predicts which atopic dermatitis patients will respond to JAK inhibitors, showing 5.5x better outcomes for identified responders versus alternative treatments.
CSTLpersonalized medicineatopic dermatitis